The stock's fall snapped a two-day winning streak.

Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this month.

Dr. Robert A. Winn discusses efforts to increase diversity in clinical trials on an episode of Radio Health Journal.

Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subc ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

In 2023, drug companies launched new medications at prices 35 percent higher than the year before. On January 1, Pfizer ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of unusually large options trading activity on Thursday. Stock investors acquired 296,826 call options on the company. This is an ...

Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...

Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of ...

This was the stock's second consecutive day of gains.

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 203,938 calls trading, 22x expected, and implied vol increasing over 5 points to 22.90%. Jan-25 52.5 calls and Jan-25 50 calls are the ...